玻璃体腔注射Avastin治疗病理性近视黄斑CNV 的临床观察
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Clinical observation on pathologic myopia CNV treated with intravitreal bevacizumab
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察病理性近视(pathologic myopia,PM)黄斑脉络膜新生血管(choroidal neovascularization,CNV)经Avastin治疗后眼部病变和最佳矫正视力(best corrected visual acuity,BCVA)变化,结合光相干断层扫描(optical coherence tomography,OCT),荧光素眼底血管造影(fluorescence fundus angiography,FFA)的结果,评价Avastin治疗PM黄斑CNV的临床疗效和安全性。

    方法:PM黄斑CNV 41例42眼,随机分为两组,试验组21例22眼采用玻璃体腔注射Avastin联合口服复方血栓通胶囊治疗; 对照组20例20眼仅口服复方血栓通胶囊治疗,剂量、疗程同实验组。两组随访时间均为12mo,统计分析两组BCVA、眼底检查、FFA及OCT检查结果,评价Avastin治疗PM黄斑CNV的临床疗效和安全性。

    结果:BVCA:试验组平均提高4.23±2.02行,对照组平均提高1.95±1.90行,组间差异有统计学意义(P<0.005),试验组提高较对照组明显; OCT:比较两组中央视网膜厚度(central foveal thickness,CFT),试验组和对照组减低平均值分别是43.41±40.39和22.65±20.79μm,组间差异有统计学意义(P<0.05),实验组CFT减低程度较对照组明显; FFA:治疗后试验组20眼(91%)渗漏消失,2眼(9%)渗漏持续存在; 对照组12眼(60%)完全消失,8眼(40%)持续存在,组间差异有统计学意义(P<0.05),实验组渗漏明显减轻。

    结论:Avastin可有效减轻病理性近视CNV的渗漏,缩短病程,提高视力,治疗安全。

    Abstract:

    AIM: To evaluate the efficacy and safety of intravitreal bevacizumab(Avastin)for choroidal neovascularization(CNV)in pathologic myopia(PM)by including optical coherence tomography(OCT), fluorescein angiography(FFA)and best-corrected visual acuity(BCVA).

    METHODS: Totally 42 eyes in 41 patients with PM CNV were divided into 2 groups randomly, experimental group(n=22)were assigned to receive intravitreal bevacizumab injections and take fufangxueshuantong capsule; control group(n=20)just took fufangxueshuantong capsule. Subjects were followed up every month after treatment. The efficacy and safety of two group were compared by ophthalmic evaluations including OCT, FFA, and BCVA.

    RESULTS: BCVA: BCVA in two groups was improved after 12 months. The mean number of treatments per eye, experimental group was 4.23±2.02 and control group was 1.95±1.90. There was significant difference(P<0.005). OCT: Before and after 12 months central foveal thickness(CFD)for two groups were thin,and the mean value in experimental group was 43.41±40.39μm and in control group was 22.65±20.79μm, there was significant difference(P<0.05); FFA: In experimental group CNV was completely disappeared in 20 eyes(91%), persistent in 2 eyes(9%); the control group CNV was completely disappeared in 12 eyes(60%), persistent in 8 eyes(40%). There was significant difference(P<0.05).

    CONCLUSION: Intravitreal bevacizumab are safe and effective treatment for most patients of CNV in PM.

    参考文献
    相似文献
    引证文献
引用本文

刘政群,朱小华,岳辉.玻璃体腔注射Avastin治疗病理性近视黄斑CNV 的临床观察.国际眼科杂志, 2013,13(5):953-956.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2013-03-02
  • 最后修改日期:2013-04-19
  • 录用日期:
  • 在线发布日期: 2013-05-06
  • 出版日期:
文章二维码